State Street Corp Prometheus Biosciences, Inc. Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$103.46 - $126.29 $10.8 Million - $13.2 Million	-104,609 Reduced 7.76%	1,243,571 $133 Million
Q4 2022 Feb 14, 2023	SELL	$36.06 - $117.21 $8.58 Million - $27.9 Million	-237,894 Reduced 15.0%	1,348,180 $148 Million
Q3 2022 Nov 15, 2022	BUY	$28.17 - $59.01 $31 Million - $65 Million	1,100,857 Added 226.88%	1,586,074 $93.6 Million
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $11.2 Million - $19.6 Million	-502,243 Reduced 50.86%	485,217 $13.7 Million
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $16.5 Million - $27.3 Million	546,100 Added 123.73%	987,460 $37.3 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $5.44 Million - $9.65 Million	244,094 Added 123.74%	441,360 $17.5 Million
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $866,203 - $1.12 Million	41,465 Added 26.61%	197,266 $4.68 Million
Q2 2021 Aug 16, 2021	BUY	$16.8 - $29.65 $2.62 Million - $4.62 Million	155,801 New	155,801 $3.83 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.